Competitve threats remain for Cochlear

Cochlear (COH, Reduce, Price Target A$79.93) - An AFR article out last week highlights growing competition for cochlear implants (CIs) in China, with COH optimistic its product innovation and sector growth, especially in the ageing adult market, will allow it to offset these competitive threats and drive sales. Although shares are down 12% since we resumed coverage with a Reduce rating back in March (vs ASX200 c5%) and are flirting around our A$79.93 price target, we see further downside risk and are hesitant to call a bottom. We continue to lack confidence in strong underlying CI growth, with ongoing competitive pressure limiting earnings visibility and share levels extended (FY16 PE 25.8x vs 23x 5 year average; EV/EBITDA 16.9x vs 15x 5 year average).


1 topic

1 stock mentioned

Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.